214 related articles for article (PubMed ID: 9179190)
1. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma.
Fernandez-Pol JA; Fletcher JW; Hamilton PD; Klos DJ
Anticancer Res; 1997; 17(3A):1519-30. PubMed ID: 9179190
[TBL] [Abstract][Full Text] [Related]
2. Metallopanstimulin as a novel tumor marker in sera of patients with various types of common cancers: implications for prevention and therapy.
Fernandez-Pol JA
Anticancer Res; 1996; 16(4B):2177-85. PubMed ID: 8694540
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of MPS antigens by squamous cell carcinomas of the head and neck: immunohistochemical and serological correlation with FDG positron emission tomography.
Stack BC; Dalsaso TA; Lee C; Lowe VJ; Hamilton PD; Fletcher JW; Fernandez-Pol JA
Anticancer Res; 1999; 19(6C):5503-10. PubMed ID: 10697607
[TBL] [Abstract][Full Text] [Related]
4. Metallopanstimulin is overexpressed in a patient with colonic carcinoma.
Ganger DR; Hamilton PD; Fletcher JW; Fernandez-Pol JA
Anticancer Res; 1997; 17(3C):1993-9. PubMed ID: 9216656
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of metallopanstimulin/S27 ribosomal protein in hepatic regeneration and neoplasia.
Ganger DR; Hamilton PD; Klos DJ; Jakate S; McChesney L; Fernandez-Pol JA
Cancer Detect Prev; 2001; 25(3):231-6. PubMed ID: 11425264
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin.
Santa Cruz DJ; Hamilton PD; Klos DJ; Fernandez-Pol JA
J Cutan Pathol; 1997 Oct; 24(9):533-42. PubMed ID: 9404850
[TBL] [Abstract][Full Text] [Related]
9. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
11. Increased serum level of RPMPS-1/S27 protein in patients with various types of cancer is useful for the early detection, prevention and therapy.
Fernandez-Pol JA
Cancer Genomics Proteomics; 2012; 9(4):203-56. PubMed ID: 22798506
[TBL] [Abstract][Full Text] [Related]
12. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
13. [Vascular endothelial growth factor in patients with prostate cancer and benign prostatic hyperplasia].
Trapeznikova MF; Shibaev AN; Kazantseva IA; Mironova OS; Gurevich LE; Morozov AP; Urenkov SB; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 2005; (5):14-6. PubMed ID: 15960197
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
15. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
16. Bone scanning--who needs it among patients with newly diagnosed prostate cancer?
Hirobe M; Takahashi A; Hisasue S; Kitamura H; Kunishima Y; Masumori N; Iwasawa A; Fujimori K; Hasegawa T; Tsukamoto T
Jpn J Clin Oncol; 2007 Oct; 37(10):788-92. PubMed ID: 17911377
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
[TBL] [Abstract][Full Text] [Related]
18. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
20. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
